Risks of tuberculosis, meningitis, candidiasis and fungal infections in patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data
Open Access
- 15 September 2026
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Abstract
Background: Systemic treatments for psoriasis confer differential risk profiles for infections such as tuberculosis (TB), meningitis, candidiasis and other fungal infections. However, real-world comparative data including interleukin (IL)-17 and IL-23 inhibitors remain limited. Methods: We conducted a nationwide cohort study using data from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) from 2007 to 2024. Adults with psoriasis receiving systemic treatments were included and followed from treatment initiation until treatment discontinuation, death or last available follow-up data. Primary outcomes included TB, meningitis, candidiasis and other fungal infections. Incidence rates per 1000 person-years (PY) were calculated and incidence rate ratios (IRRs) were estimated using a doubly robust interval-based Poisson regression model. An entropy balancing method was used to achieve covariate balance across treatment groups and multiple imputation was used to handle missing baseline data. Results: A total of 40 930 treatment episodes from 18 635 patients contributing 118 018 PY of follow-up were included in this analysis. During the follow-up, 22 TB cases, 29 meningitis cases and 888 fungal infection cases, including 450 cases of candidiasis, were reported. The overall incidence rates were 0.18 [95% confidence interval (CI) 0.12–0.28] for TB, 0.25 (95% CI 0.16–0.35) for meningitis and 7.53 (95% CI 7.05–8.05) for fungal infections per 1000 PY. Most TB and meningitis cases were associated with tumour necrosis factor-α inhibitors, particularly adalimumab. Meningitis was predominantly viral and TB was largely pulmonary. Thirty-day mortality was seen in < 5 cases in meningitis. IL-17 inhibitors alone exhibited an increased risk of candidiasis compared with all other systemic treatment groups, with IRRs ranging from 2.67 (95% CI 1.33–5.36) vs. apremilast to 4.65 (95% CI 3.46–6.24) vs. the IL-12/23 inhibitor. Individual IL-17 inhibitors did not exhibit significant differences in the risk of candidiasis. With fungal infections other than candidiasis, no statistically significant differences were observed between treatment groups. Conclusions: In this large cohort study, TB and meningitis were rare and longer-term follow-up is required to further characterize the risk with newer treatments. Candidiasis and fungal infections were more common with increased risks in patients receiving IL-17 inhibitors.Keywords
Funding Information
- British Association of Dermatologists
- BADBIR
- Psoriasis Association
- National Institute for Health and Care Research
- National Institute on Handicapped Research
- Manchester Biomedical Research Centre (203308)
- NIHR Newcastle Biomedical Research Centre
- NIHR Newcastle Patient Safety Research Centre
- NIHR Newcastle Health Tech Research Centre
This publication has 26 references indexed in Scilit:
- Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsJournal of the American Academy of Dermatology, 2025
- Risk of fungal infection in psoriasis patients treated with IL-17 and IL-23 inhibitors: a multi-cohort study using real-world dataArchives of Dermatological Research, 2025
- Risk of fungal infection in patients with psoriasis receiving biologics: A retrospective single-center cohort studyJournal of the American Academy of Dermatology, 2024
- Biologics and candidiasis incidence: Minimally rising yeastJournal of the American Academy of Dermatology, 2024
- Immunological Effects of Anti‒IL-17/12/23 Therapy in Patients with Psoriasis Complicated by Candida InfectionsJournal of Investigative Dermatology, 2022
- Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sourcesThe Lancet Regional Health - Europe, 2021
- Serious infections among a large cohort of subjects with systemically treated psoriasisJournal of the American Academy of Dermatology, 2017
- Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti–tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registriesJournal of the American Academy of Dermatology, 2017
- Cryptococcal Meningitis in Patient with Rheumatoid Arthritis treated with Infliximab and RituximabJournal of Infection, 2011
- Pneumococcal meningitis and etanercept—chance or association?Journal of Infection, 2005